These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19794997)

  • 1. Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.
    Kang H; Kim TJ; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
    J Korean Med Sci; 2009 Oct; 24(5):945-50. PubMed ID: 19794997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.
    Shin W; Lee HJ; Yang SJ; Paik ES; Choi HJ; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
    Obstet Gynecol Sci; 2018 May; 61(3):352-358. PubMed ID: 29780777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study.
    Shaheen M; Stender MJ; McClean JW; Look KY; Einhorn LH
    Am J Clin Oncol; 2004 Jun; 27(3):229-31. PubMed ID: 15170139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
    El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
    Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.
    Song T; Kim MK; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):653-60. PubMed ID: 23912693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma.
    Baker TR; Piver MS; Hempling RE
    Eur J Gynaecol Oncol; 1993; 14(1):18-22. PubMed ID: 8472726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide and etoposide salvage treatment in advanced ovarian cancer.
    Bruzzone M; Campora E; Merlini L; Giudici S; Bottero G; Iskra L; Donadio M; Ferrari I; Ragni N
    J Chemother; 1991 Oct; 3(5):332-4. PubMed ID: 1809812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
    Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
    Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer.
    Aravantinos G; Dimopoulos MA; Kosmidis P; Bafaloukos D; Papadimitriou C; Kiamouris C; Pavlidis N; Sikiotis K; Papakostas P; Skarlos DV
    Ann Oncol; 2000 May; 11(5):607-12. PubMed ID: 10907957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.
    Joly F; Sevin E; Lortholary A; Priou F; Paitel JF; Fabbro M; Henry-Amar M; Hamond K; Bourgeois H
    Gynecol Oncol; 2010 Mar; 116(3):312-6. PubMed ID: 19887304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer].
    Chauvergne J; Chinet-Charrot P; Stöckle E; Thomas L; Toulouse C
    Bull Cancer; 1996 Apr; 83(4):315-23. PubMed ID: 8680083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.
    Fanning J; Hilgers RD; Hutson E
    Am J Clin Oncol; 1994 Aug; 17(4):335-7. PubMed ID: 8048396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
    Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH
    Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
    Chamberlain MC; Glantz MJ
    Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.